Oric Pharmaceuticals Inc

For the period ended Dec 31, 2024. Filed Feb 18, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Feb 18, 2025

ORIC$9.23+4.6%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Balance Sheets

(in thousands, except share and per share amounts)

	December 31,
	2024	2023
Assets
Current assets:
Cash and cash equivalents	$59,406	$23,384
Short-term investments	196,554	184,803
Prepaid expenses and other current assets	6,290	4,410
Total current assets	262,250	212,597
Long-term investments	—	26,852
Property and equipment, net	2,924	2,862
Other assets	8,968	9,696
Total assets	$274,142	$252,007
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable	$1,548	$944
Accrued liabilities	23,298	19,514
Total current liabilities	24,846	20,458
Other long-term liabilities	6,174	7,461
Total liabilities	31,020	27,919
Commitments and contingencies
Stockholders' equity:
Preferred stock, $0.0001 par value; 200,000,000 shares authorized; no shares issued and outstanding at December 31, 2024 and 2023	—	—
Common stock, $0.0001 par value; 1,000,000,000 shares authorized; 71,021,855 and 54,865,553 shares issued and outstanding at December 31, 2024 and 2023, respectively	7	6
Additional paid-in capital	805,510	658,751
Accumulated deficit	(562,774)	(434,927)
Accumulated other comprehensive income	379	258
Total stockholders' equity	243,122	224,088
Total liabilities and stockholders' equity	$274,142	$252,007

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.